InvestorWire NewsRoom

Articles

Articles Category: Psychedelics
Wednesday Jun 09, 2021 - 9:00 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Inks White Label Agreement as Strategic Planning Pays Off

White label agreement with FLO Brands outlines launch of cannabis vape product linePULL beginning to execute strategy to get white label products into provincial dispensaries, drive up to $3 million of annual revenueNikolaevsky reports that “white labeling has also begun to build momentum and gain sales traction for us” Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis,…

Continue Reading

Friday Jun 04, 2021 - 9:30 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Opens Direct-To-Consumer Amazon Store under Pure Mushrooms Brand

PULL subsidiary Pure Mushrooms Corp. opens direct-to-consumer e-Commerce store on Amazon platformStore features Reishi, Maitake formulations with plans to add Lion’s Mane in summer 2021Global functional mushroom market valued at $25.4 billion in 2020, expected CAGR of 8.44% from 2021-2026Company expands psychedelic vertical through letter of intent with Psyence Group to co-produce psychedelic mushroom-based psilocybin formulations Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ),…

Continue Reading

Thursday Jun 03, 2021 - 10:24 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Notes Impressive Advancement in Cannabis, Functional Mushrooms, Psilocybin Spaces

Pure Extracts’ BC facility is fully operational, ready to meet increasing demand for cannabis-based gummies, vapes, white label productsCompany’s involvement in functional, psychoactive mushrooms space is also gaining steamPure Extracts’ current R&D focus is on psychoactive mushroom compounds Although the global pandemic extended its sales cycle, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is seeing interest from producers and brands looking for new opportunities and…

Continue Reading

Thursday Jun 03, 2021 - 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Targets Academic Collaborations to Advance Research on Largely Ignored Indications for Psilocybin

Psychedelics have been on the receiving end of groundbreaking research, which have greatly influenced the medical acceptance of the compoundsPharmaceutical developer Tryp Therapeutics is looking to use existing preclinical and clinical data to proceed directly to Phase 2a clinical trialsThe company intends to contribute to the growing body of research through academic collaborations with leading American institutions The research will focus on indications that other pharmaceutical…

Continue Reading

Wednesday Jun 02, 2021 - 9:15 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Beginning 2021 Strong with New Drugs and Life Sciences Advancements

Promising results have been recorded in the first pilot study of a Rotigotine skin patch for Parkinson’s patientsWholly owned subsidiary Vektor is reaching a major milestone in the development of Rotigotine with the potential for a pivotal human trialThe company is planning the construction of a new lab and manufacturing space up to 32,000 square feet in Biberach, GermanyPilot project involving rapid COVID-19 PCR tests…

Continue Reading

Friday May 28, 2021 - 11:33 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Building Psychedelic Medicine Program on Foundation of Strong Leadership, Pharmaceutical Alliances

Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needsTryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indicationsThe company expects to begin manufacturing its initial oral psilocybin formulation in September 2021Tryp’s scientific and executive team has decades of experience in large pharma, emerging pharma, drug approvals, psychedelics and…

Continue Reading

Wednesday May 26, 2021 - 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio 

Company files 12th patent to strengthen proprietary IP programCybin believes treatments can decrease costs, increase access to important therapeuticsPatent provides wide range of benefits in Cybin’s four drug candidate program Cybin (NEO: CYBN) (OTCQB: CLXPF) has filed a new provisional patent application designed to strengthen the company’s ongoing drug candidate programs (https://ibn.fm/9V5sv). Cybin, a biotechnology company focused on progressing psychedelic therapeutics, is focused on expanding…

Continue Reading

Monday May 24, 2021 - 1:50 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts

Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needsThe company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disordersTryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering drugs to treat select neurological conditions when paired with the care of…

Continue Reading

Tuesday May 18, 2021 - 9:15 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Targets Potential Expansion of Rapid COVID-19 Test Kit Distribution with Delivery of 2,000 Units to Israel

XPhyto recently delivered 2,000 of its rapid Covid-ID Lab test kits to an established Israeli distributor for clinical evaluation by the Ministry of HealthThe delivery, which marks entry into the Middle East, follows the approval of the test kits in EuropeIn an earlier interview, CEO Hugh Rogers had noted that XPhyto was looking to expand distribution to various markets, including the Middle East In an…

Continue Reading

Friday May 14, 2021 - 12:07 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Maintains Buy Rating in Recent Equity Update

April analyst reports all point to a bright future for Cybin“CYBN is a true multi-molecule company that's not being reflected in its valuation,” reports Stifel“With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined,” notes Roth A series of recent analyst reports bodes well for Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing…

Continue Reading

Thursday May 13, 2021 - 12:06 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders

Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needsTryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagiaThe company is also developing a clinical trial to address the needs of fibromyalgia patients who often rely on opioids to relieve their symptomsTryp has…

Continue Reading

Tuesday May 11, 2021 - 1:18 pm

Business Booming in April: Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Lands Tolling Agreement to Extract CBD from 500 Kg Hemp Biomass

CBD-infused products market is expected to grow 48.1% annually to reach $165.7 billion by 2027Pure Extracts Technologies’ subsidiary recently began production of goods expected to generate approximately $950,000 in revenueNew tolling agreement is for extraction of 80-85% pure CBD distillate from an initial 500 kilograms (~1,102 pounds) of hemp biomass Any industry forecast for double-digit growth is one worth keeping an eye on. When experts…

Continue Reading

Monday May 10, 2021 - 12:19 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Looks to New Senior Management with Expertise in Development, Clinical Capabilities

Company committed to building presence in U.S. and Europe to advance mission of improving mental health careNew appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industryNew leaders bring broad experience, deep insight to their new roles Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, recently made key senior-management changes designed to provide the company…

Continue Reading

Friday May 07, 2021 - 1:47 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Investigates Alleviating Neurological Disorders with Psychedelics

Tryp Therapeutics is a pharmaceutical developer working to produce novel bioscience solutions, including a synthetic psychedelic drug candidate for treating some chronic pain and eating disordersTryp CEO Greg McKee appeared on the Entrepreneur Magazine podcast “Action and Ambition” earlier this month to discuss lessons learned on his road to success and to highlight the company’s purpose in developing treatments for helping people be more wholePsychedelic…

Continue Reading

Wednesday May 05, 2021 - 12:07 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Signs Drug-Development Agreement, One Step Closer to Effective Psychiatric Disorder Treatment 

Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disordersCybin looking to identify fast-acting, shorter-duration formulations of CYB003Delivering CYB003 through Catalent ODT could provide significant benefits Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development, and…

Continue Reading

Tuesday May 04, 2021 - 2:27 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Distribution Agreement for Rapid COVID-19 Test Kits; Expands Commercial Leadership Team in Anticipation of Strong, Sustainable Sales 

XPhyto Therapeutics Corp. recently announced it has entered into a distribution, storage and logistics agreement with a German distributor with an established network throughout GermanyGermany holds promise due to regulations requiring mandatory weekly testing for its citizens; this has the possibility of ramping up salesAnticipating the increase in sales and distribution, XPhyto expanded its commercial leadership team by bringing on board Mr. Wolfgang Probst and…

Continue Reading

Tuesday May 04, 2021 - 11:48 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Charge in Developing Psychedelic Medicines for Treating Rare Eating Disorders

Pharmaceutical developer Tryp Therapeutics is targeting orphan disorders with novel medicinal solutionsThe company’s initial candidates seeking regulatory approval are a psilocybin compound for treating fibromyalgia, eating disorders and chronic pain conditions, as well as a tumor-inhibiting drug for treating soft tissue sarcomasTryp has partnered with the University of Florida to conduct a Phase 2a clinical trial for eating disorders using Tryp's psilocybin product Following a…

Continue Reading

Monday May 03, 2021 - 1:07 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Makes Headway into Canadian Cannabis Vape Market with 25,000 Unit Production Run

Production underway for 25,000 vape cartridges using PULL full spectrum oil formulations, including Super Lemon Haze, Grand Daddy Purple and Girl Scout Cookies/GSKCompany estimates retail sales revenue for this production run will be approximately $750,00060% of respondents in StatCan’s Canadian 2020 Cannabis Survey that used vaporizer for cannabis in the last 12 months used oil/extracts “Cannabis 2.0,” the colloquial term for legalization of cannabis derivatives…

Continue Reading

Friday Apr 30, 2021 - 1:53 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Is ‘One to Watch’

Tryp Therapeutics is a pharmaceutical company with a focus on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathwaysThe company currently has two drug candidates in development: TRP-8802 (targeting fibromyalgia, eating disorders and chronic pain conditions); and TRP-1001 (targeting soft tissue sarcomas)Through its PFN(TM) program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that offer…

Continue Reading

Wednesday Apr 28, 2021 - 12:04 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Retail Business to Bloom This Spring With Production of 50,000 Blister Packs

PULL starts production of roughly 50,000 blister pack gummies using Taste-T LLC’s successful proprietary manufacturing systemGlobal CBD gummies market size estimated to grow at CAGR of 31.9% until 2025 PULL estimates $200,000 in revenue from initial batch, plans to produce three additional non-THC SKUs with varying levels of ultra-high potency CBD Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on…

Continue Reading

Friday Apr 16, 2021 - 12:16 pm

Largely Untapped Market for Hallucinogenic Draws Attention of Researchers at XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

XPhyto Therapeutics Corp., a life sciences technology accelerator, is looking for ways to turn promising psychedelics into therapeutic pharmaceutical drugs, and recently added mescaline to its study profileMescaline is illegal under U.S. federal law, but some state-centric efforts to legalize or decriminalize the hallucinogenic have launched in a manner similar to the populace effort that produced a wave of cannabis product legalizationMescaline has historically defied…

Continue Reading

Monday Apr 12, 2021 - 1:02 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Files First Order for Rapid COVID Test Kits Amid European Regulatory Approval

Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partnerXPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standardsThe Covid-ID Lab is designed to help beleaguered…

Continue Reading

Tuesday Apr 06, 2021 - 1:23 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes Pre-Clinical Studies, Progresses Two Drug Candidates

Cybin has completed more than 20 pre-clinical studies in record time.Company is advancing two new therapeutic candidates with enhanced, improved properties.Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs. Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies both in vitro and in vivo. The company recently announced that it had completed its…

Continue Reading

Monday Mar 29, 2021 - 11:53 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Orders First Functional Mushroom Shipment for Global E-Commerce Portal

PULL expands into EU through initial sale of cannabis oil extracts to German pharmaceutical companySale to Germany expected to pave way for additional supply agreements throughout EuropeCompany orders first shipment of functional mushroom products for direct-to-consumer e-commerce portal, expects $15,000 gross monthly sales for each formulationPULL’s new state-of-the-art facility constructed to EU GMP standards for worldwide exports With a focus on the cannabis, hemp, functional…

Continue Reading

Monday Mar 22, 2021 - 11:39 am

Pure Extracts Technologies Corp.’s (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Subsidiary Pure Mushrooms Corp. Submits Application to Health Canada for a Dealer’s License

Pure Extracts Technologies Corp.’s subsidiary Pure Mushrooms Corp. has submitted an application to Health Canada for a Dealer’s LicenseAward of a Dealer’s License will enable company to procure controlled substances, conduct research, carry out business-to-business salesPure Extracts has recently commenced a study into psilocybin-based active treatments, with research set to be carried out under auspices of Toronto Institute of Pharmaceutical TechnologyFunctional mushroom, psychedelic drug market…

Continue Reading

Wednesday Mar 17, 2021 - 3:09 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Takes Milestone Step Toward Offering Product Across Canada

PULL subsidiary has submitted application to Health Canada to amend license to permit sales of productThe submission follows recent announcement that Pure Extracts inked distribution agreement with an important Canadian Licensed Producer (“LP”)PULL plans on distributing exclusive vape, edible products to retail buyers across Canada As a result of the its recently inked distribution agreement with an important Canadian LP, Pure Extracts Technologies (CSE: PULL) (OTC:…

Continue Reading

Tuesday Mar 09, 2021 - 3:09 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Upsizes Its Bought Deal Offering Due to Surge in Demand

Cybin's latest offering generated exceptional demand; announces upsize of "bought deal" offeringBurgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments.Cybin appears set for rapid growth as research accelerates, public acceptance grows. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotech company focused on psychedelic therapeutics for various psychiatric and neurological conditions, has announced that it has upsized the terms of its…

Continue Reading

Monday Mar 08, 2021 - 11:08 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) and Canada House Wellness Group (CSE: CHV) Partner, Bringing New Cannabis 2.0 to More Canadians

Canada House subsidiary Abba Medix to distribute Pure Extract line of full spectrum oil vape and edible products throughout its nationwide networkPartnership widens Pure Extracts’ footprint in Canada’s growing Cannabis 2.0 marketGlobal extraction product market expected to reach $28.5 billion in next six yearsNew agreement strengthens Pure Extracts’ sales channels as it looks towards international expansion There’s plenty of media coverage about increasing legalization of…

Continue Reading

Thursday Mar 04, 2021 - 12:14 pm

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Newly Acquired Subsidiary Achieves Earn-Out Milestone —Successful Synthesis of Multiple Tryptamine Derivatives

Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with CybinAdelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health spaceAcquisition results in Cybin obtaining extensive intellectual property portfolio and product pipeline Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has announced that its recently acquired…

Continue Reading

Thursday Feb 25, 2021 - 12:28 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Inks First CBD Oil Commercial Sale; Looks to Grow in Key Spaces

Pure Extracts is preparing to deliver shipment of 85% pure CBD distillateCompany proud of quality offering produced in world-class facilityPULL uses proprietary state-of-the art, sub-critical/super-critical CO2extraction system Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company, has signed a contract for its first CBD oil commercial sale on the wholesale market (https://ibn.fm/92kPG). Pure Extracts is preparing to deliver the first of what it anticipates…

Continue Reading

Thursday Feb 18, 2021 - 10:00 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters Large Cannabis Biomass Agreements to Scale Up Extract Production, Announces DTC Eligibility of Common Shares in the U.S.

Pure Extracts entered into two large biomass purchase agreements, plans to ramp up production of high-potency THC and CBD extracts in 2021Company expects historically low biomass purchase price will produce $590,000 revenueCompany recently announced DTC eligibility of common shares for increased settlement and clearance speeds, wider access to brokerage firms Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company that focuses…

Continue Reading

Tuesday Feb 16, 2021 - 2:14 pm

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Delineates Parameters and Timeline of Study into Psilocybin-Based Active Treatments

Pure Extract Technologies pursues study into psilocybin active treatmentsStudy to extend for 250-day period, targeting a number of milestonesThe study is set to be carried out at Toronto Institute of Pharmaceutical Technology, will be supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregorOregon recently voted to legalize psilocybin mushrooms for therapeutic use, a potential legislative movement which may soon be replicated in other jurisdictions Pure…

Continue Reading

Wednesday Feb 03, 2021 - 2:55 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Updates Investors Following Completion of Special Warrants Private Placement

Pure Extracts recently updated investors on successful completion of second tranche of its special warrants private placementIn aggregate, Company will raise gross proceeds of $8.5 million through both tranches of private placementPure Extracts will employ net proceeds from private placement towards capacity expansion for Company’s extraction business, and for general working capital purposesCompany previously revealed that it was conducting study looking into formulation, manufacturing of…

Continue Reading

Tuesday Feb 02, 2021 - 3:32 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Is ‘One to Watch’

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunitiesThe company has research and development operations in North America and Europe and an operational focus in GermanyXPhyto’s operations are concentrated into three core divisions: infectious disease diagnostics, clinical development of transdermal and sublingual drug formulations, and psychedelic medicineThe company’s lead diagnostic product is an accurate,…

Continue Reading

Thursday Jan 28, 2021 - 11:44 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Increases Private Placement, Begins Trading on OTC Market

Pure Extracts upsizes private placement to total 16,900,000 special warrants at price of $0.505.PULL also received approval from OTC Markets, is trading on OTC Market under ticker symbol PRXTF.Trading under new OTC ticker is “major step forward,” says Company CEO. Pure Extracts Technologies (CSE PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company, has increased its non-brokered private placement offering of special warrants; the original…

Continue Reading

Wednesday Jan 20, 2021 - 2:14 pm

Cybin Inc. (NEO: CYBN) Announces Partnership with Neurotech Pioneer to Leverage Innovative Technology for Psychedelic Therapeutics

CYBN partners with pioneer company focused on exploring, quantifying the human mindInnovative Flow technology adds exciting dimension to Cybin’s commitment to develop breakthrough treatments for mental health disordersInnovative technology opens new frontier in psychedelic therapeutics Cybin (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is partnering with neurotech pioneer HI, LLC dba Kernel to quantify brain activity in…

Continue Reading

Wednesday Jan 20, 2021 - 1:59 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Commences Research into Psilocybin-Based Active Treatments

Pure Extracts commences study into psilocybin-based active treatmentsStudy set to be carried out at Toronto Institute of Pharmaceutical Technology, supervised by Pure Extracts’ scientific advisor, Dr. Alexander MacGregorStudy will delve into carrying out conformity testing, stability testing for psilocybin products thereby commencing the R&D that will ultimately take place at Pure Extracts’ purpose-built research space at its facility in British ColumbiaFunctional mushroom, psychedelic drug market…

Continue Reading

Tuesday Jan 12, 2021 - 11:02 am

Health Canada Grants Selected Physicians Access to Psilocybin Mushrooms as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Dives into Functional Mushroom Market

Health Canada recently granted psilocybin testing access to selected physiciansPsilocybin mushrooms shown to help patients suffering from addiction, mental health issuesPure Extracts’ ’Pure Mushrooms’ and ‘Pure Pulls’ branded products expected to be available by end of Q1 2021 In a recent virtual townhall, Canadian Health Minister Patty Hajdu disclosed that the Canadian government has recently granted access to psilocybin or “psychedelic” mushrooms to several physicians…

Continue Reading

Wednesday Jan 06, 2021 - 1:58 pm

Pure Extracts Technologies (CSE: PULL) Draws Out Expansion Plans in Anticipation of Regulatory Changes Within Mushroom Sector

Pure Extracts Technologies Corp. has announced plans to expand, build fourth unit in dedicated towards research, development of psilocybinAnnouncement on its expansion plans come shortly after the Company revealed it plans to apply to Health Canada for a Dealer’s LicenseAward of Dealer’s License would allow Pure Extracts to cultivate, harvest and procure controlled substances and carry out research into psychedelic compounds such as psilocybin and…

Continue Reading

Tuesday Jan 05, 2021 - 1:02 pm

Cybin Inc. (NEO: CYBN) R&D Sees Hope in Growing Acceptance of Psilocybin

U.S. taking actionable steps toward acceptance of psilocybinStates, individual cities have decriminalized, made use and possession of psilocybin low law-enforcement priorityMore psilocybin research being done focused on health, well-being of Americans facing a mental health crisis on epic levels Cybin (NEO: CYBN) is a life science company focused on the pharmaceutical development of psychedelic products. The company's subsidiary Serenity Life Sciences is focused on the…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).